<DOC>
	<DOCNO>NCT02075528</DOCNO>
	<brief_summary>Paliperidone ER new psychotropic medication schizophrenia treatment . The study 6-week acute treatment 52-week maintenance treatment show positive result patient schizophrenia clinical improvement may start Day 4 . Some second-generation antipsychotic find use first 2 week ' treatment result predict fourth sixth week 's treatment response acceptable . The primary aim study investigate : 1. . whether early prediction model use atypicals could also apply paliperidone ER . 2. . The change metabolic parameter pharmacokinetics paliperidone ER treatment study</brief_summary>
	<brief_title>Early Prediction Clinical Response Patients With Schizophrenia Treated Paliperidone ER</brief_title>
	<detailed_description>Patients diagnose schizophrenia schizoaffective disorder enrol 6-week trial . Eligible patient receive 9mg paliperidone ER first . Then , dosage paliperidone could adjust two week later accord clinical judgement . They follow receive assessment pharmacokinetics , metabolic parameter ( lipid profile , glucose , insulin , adiponectin , leptin , prolactin , etc . ) , treatment response .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>diagnosis schizophrenia schizoaffective disorder accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) minimal baseline total score 60 PANSS receive longacting antipsychotic injection precede 6 month physically healthy standard clinical laboratory test result within laboratory reference range , outside range , judge clinically insignificant investigator . diagnosis substance ( include alcohol ) dependence previous 6 month medical condition could affect absorption , metabolism , excretion study drug substantial risk suicide violent behavior pregnancy breastfeed document organic disease central nervous system unstable critical untreated medical illness history clozapine treatment previous 3 month participation investigational drug trial 30 day screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Paliperidone</keyword>
	<keyword>Treatment response</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Early prediction</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>